Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, Oridis to Offer Protein-Biomarker Services

NEW YORK (GenomeWeb News) — Expression Pathology has formed an alliance with the Austrian company Oridis Biomed to offer proteomic tissue-analysis services for protein biomarker research, the companies said today.
Under the agreement, both companies will be able to offer the collaborative research services to clients in the drug-development, medical-diagnostic, and academic spheres.
The collaboration will use Expression Pathology’s Liquid Tissue and Director mass spectrometry and proteomics technologies, along with Oridis’ Tissomics high-throughput platform, and its access to formalin-fixed tissue samples.
Expression Pathology CEO Casey Eitner said the alliance will help drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity.
Oridis CEO Peter Hecht said the collaboration will allow companies to use mass spec and other pathology techniques to “mine tissue archives with detailed clinical outcomes and pathology data."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.